{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:15:57Z","timestamp":1788419757725,"version":"build-2803163510"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced toxicity remains a major cause of treatment discontinuation, reduced quality of life, and long-term morbidity in cancer survivors. Established chemoprotective agents (dexrazoxane, mesna, and amifostine) are limited by narrow indications (dexrazoxane: only anthracycline cardiotoxicity), significant adverse effects (amifostine: hypotension in 62%), and lack of efficacy against common toxicities such as peripheral neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This focused review evaluates emerging chemoprotective strategies with preclinical or early clinical data published between 2015 and 2025, with an emphasis on agents that address unmet clinical needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a critical narrative review, not a systematic review. A literature search was conducted in PubMed, Scopus, and\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      (2015\u20132025) using keywords including \u201cchemoprotection,\u201d \u201cnanoparticle,\u201d \u201ccurcumin,\u201d \u201cresveratrol,\u201d \u201cdual COX-2\/TNF-\u03b1 inhibitor,\u201d \u201cNrf2 modulator,\u201d and \u201cchemotherapy-induced peripheral neuropathy.\u201d Articles were selected based on relevance to chemoprotection, mechanistic clarity, and availability of preclinical or clinical data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three major emerging categories were identified: (i) Nanoformulated natural products such as curcumin, resveratrol, luteolin, and naringenin encapsulated in polymeric, lipid, or cyclodextrin-based nanocarriers, demonstrate improved bioavailability and enhanced efficacy in preclinical models though chemoprotection-specific clinical data remain limited (ii) Dual COX-2\/TNF-\u03b1 inhibitors (e.g., NO-donating aspirin). simultaneously suppress inflammatory and oncogenic signaling (NF-\u03baB, \u03b2-catenin, STAT3) and have shown polyp burden reduction in familial adenomatous polyposis, though cardiovascular safety concerns persist. (iii) Nrf2 pathway modulators, including sulforaphane (activator) and brusatol (inhibitor), present a paradox: activation protects normal tissues but may also shield tumors. Physical strategies (limb hypothermia) and repurposed drugs (metformin) offer additional avenues but need Phase III validation. Emerging mechanistic frontiers including ferroptosis inhibition, pyroptosis modulation, and neuroimmune targeting represent additional promising directions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nanoformulation is the most technologically mature strategy for overcoming bioavailability barriers. Dual inhibitors offer pleiotropic benefits but require safer designs. Nrf2 modulators demand careful patient stratification. Future trials must incorporate biomarker-driven enrollment and standardized chemoprotection endpoints. Comparative analysis across categories reveals that strategies with simpler mechanisms and well-defined surrogate endpoints have advanced furthest clinically, highlighting the importance of rigorous trial design and validated biomarkers for successful translation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1907919","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:41:14Z","timestamp":1788417674000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A narrative review of emerging chemoprotective agents for chemotherapy-induced toxicity: nanoformulated natural products, dual COX-2\/TNF-\u03b1 inhibitors, and Nrf2 modulators"],"prefix":"10.3389","volume":"17","author":[{"given":"Chidi Emmanuel","family":"Ezerioha","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Basic Medical Sciences, Southern Delta University","place":["Ozoro, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious Ojo","family":"Uahomo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, University of Abuja","place":["Abuja, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious Akukanwo","family":"Chidi-Ezerioha","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Delta State University Teaching Hospital","place":["Oghara, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godwin William","family":"Akpan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Basic Clinical Sciences, University of Port Harcourt","place":["Port Harcourt, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson","family":"Chukundah","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Science, University of Port Harcourt","place":["Choba, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ejphar.2012.06.016","article-title":"Chemoprevention of azoxymethane-initiated colon cancer in rat by using a novel polymeric nanocarrier-curcumin","volume":"689","author":"Alizadeh","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.biocel.2010.09.011","article-title":"Akt is upstream and MAPKs are downstream of NF-\u03baB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism","volume":"43","author":"Bava","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"B1","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.bmc.2004.01.037","article-title":"Design, synthesis and biological evaluation of some pyrazole derivatives as anti-inflammatory-antimicrobial agents","volume":"12","author":"Bekhit","year":"2004","journal-title":"Bioorg. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3389\/fphar.2017.00354","article-title":"New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury","volume":"8","author":"Cinausero","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B8","volume-title":"NCT00348972. A Study of NCX 4016 in Patients with Familial Adenomatous Polyposis","year":"2006"},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000443404","article-title":"Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents","volume":"25","author":"Cragg","year":"2016","journal-title":"Med. Princ. Pract."},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1201\/b11185","volume-title":"Anticancer Agents from Natural Products","author":"Cragg","year":"2011"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3390\/nu11092147","article-title":"Dietary curcumin: correlation between bioavailability and health potential","volume":"11","author":"Dei Cas","year":"2019","journal-title":"Nutrients"},{"key":"B12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"DeNicola","year":"2011","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025459","article-title":"Pancreatic cancer: recent advances in nanoformulation-based therapies","volume":"36","author":"Desai","year":"2019","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-08-0024","article-title":"Phase II trial of curcumin in patients with advanced pancreatic cancer","volume":"14","author":"Dhillon","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/jnci\/djz011","article-title":"The National Cancer Institute Clinical Trials planning meeting for prevention and treatment of chemotherapy-induced peripheral neuropathy","volume":"111","author":"Dorsey","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"B38","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.toxlet.2009.11.007","article-title":"Sulforaphane protects against cisplatin-induced nephrotoxicity","volume":"192","author":"Guerrero-Beltr\u00e1n","year":"2010","journal-title":"Toxicol. Lett."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1002\/jcp.27411","article-title":"Cyclooxygenase-2 in cancer: a review","volume":"234","author":"Hashemi Goradel","year":"2019","journal-title":"J. Cell Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ccell.2020.06.001","article-title":"Oxidative stress in cancer: the Nrf2 paradox","volume":"38","author":"Hayes","year":"2020","journal-title":"Cancer Cell"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/annonc\/mdt018","article-title":"CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel","volume":"24","author":"Hertz","year":"2013","journal-title":"Ann. Oncol."},{"key":"B19","volume-title":"Bailey\u2019s Research for the Health Professional","author":"Hissong","year":"2015"},{"key":"B15","doi-asserted-by":"publisher","first-page":"F552","DOI":"10.1152\/ajprenal.00285.2002","article-title":"Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury","volume":"286","author":"Ichimura","year":"2004","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-13-0038","article-title":"Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention","volume":"3","author":"Ingle","year":"2013","journal-title":"Cancer Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ejphar.2016.07.017","article-title":"Enhanced colon cancer chemoprevention of curcumin by nanoencapsulation with whey protein","volume":"789","author":"Jayaprakasha","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3762\/bjnano.9.98","article-title":"Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations","volume":"9","author":"Jeevanandam","year":"2018","journal-title":"Beilstein J. Nanotechnol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/128_2012_339","article-title":"KEAP1-Nrf2 signaling: a target for cancer prevention by sulforaphane","volume":"329","author":"Kensler","year":"2013","journal-title":"Top. Curr. Chem."},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: a comprehensive literature review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1634\/theoncologist.12-6-738","article-title":"Amifostine: the first selective-target and broad-spectrum radioprotector","volume":"12","author":"Kouvaris","year":"2007","journal-title":"Oncologist"},{"key":"B26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2007.11.8778","article-title":"Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence","volume":"25","author":"Lipshultz","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","article-title":"Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance)","volume":"32","author":"Loprinzi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1158\/1940-6207.CAPR-13-0230","article-title":"Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity","volume":"7","author":"Majumdar","year":"2014","journal-title":"Cancer Prev. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"809308","DOI":"10.3389\/fphar.2021.809308","article-title":"Cancer chemoprevention: a strategic approach using phytochemicals","volume":"12","author":"Mohan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"14257","DOI":"10.1038\/s41598-018-32423-0","article-title":"Intranasal administration of resveratrol successfully prevents lung cancer in A\/J mice","volume":"8","author":"Monteillier","year":"2018","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","article-title":"The essential medicinal chemistry of curcumin","volume":"60","author":"Nelson","year":"2017","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J. Nat. Prod."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3390\/antiox11122345","article-title":"Nrf2 and oxidative stress: a general overview of mechanisms and implications in human disease","volume":"11","author":"Ngo","year":"2022","journal-title":"Antioxidants"},{"key":"B35","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?","volume":"9","author":"Nurgali","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/carcin\/bgv008","article-title":"Nanoparticles increase the efficacy of cancer chemopreventive agents in cells exposed to cigarette smoke condensate","volume":"36","author":"Pulliero","year":"2015","journal-title":"Carcinogenesis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/nu8110628","article-title":"Unraveling the anticancer effect of curcumin and resveratrol","volume":"8","author":"Pavan","year":"2016","journal-title":"Nutrients"},{"key":"B39","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1055\/s-0044-101752","article-title":"Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with Type 2 diabetes mellitus: a randomized double-blind placebo-controlled trial","volume":"68","author":"Panahi","year":"2018","journal-title":"Drug Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/pharmaceutics10010033","article-title":"Hyaluronic acid decorated naringenin nanoparticles: appraisal of chemopreventive and curative potential for lung cancer","volume":"10","author":"Parashar","year":"2018","journal-title":"Pharmaceutics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1476-4598-9-220","article-title":"Nicotine-induced survival signaling in lung cancer cells is dependent on their p53 status while its down-regulation by curcumin is independent","volume":"9","author":"Puliyappadamba","year":"2010","journal-title":"Mol. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fphar.2017.00019","article-title":"Delayed chemotherapy-induced nausea and vomiting: pathogenesis, incidence, and current management","volume":"8","author":"Rapoport","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt","year":"2018","journal-title":"Future Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1073\/pnas.1014275108","article-title":"Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism","volume":"108","author":"Ren","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B45","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.molmed.2004.05.004","article-title":"Nitric-oxide-donating NSAIDs as agents for cancer prevention","volume":"10","author":"Rigas","year":"2004","journal-title":"Trends Mol. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40264-023-01305-4","article-title":"The effect of metformin on chemotherapy-induced toxicities in non-diabetic breast cancer patients: a randomised controlled study","volume":"46","author":"Serageldin","year":"2023","journal-title":"Drug Saf."},{"key":"B47","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ebiom.2016.04.037","article-title":"A nexus consisting of beta-catenin and STAT3 attenuates BRAF inhibitor efficacy and mediates acquired resistance to vemurafenib","volume":"8","author":"Sinnberg","year":"2016","journal-title":"EBioMedicine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.canlet.2013.11.019","article-title":"p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents","volume":"344","author":"Sui","year":"2014","journal-title":"Cancer Lett."},{"key":"B49","doi-asserted-by":"publisher","first-page":"106476","DOI":"10.1016\/j.jff.2024.106476","article-title":"Nanotechnology-based drug delivery systems for curcumin and its derivatives in the treatment of cardiovascular diseases","volume":"122","author":"Sun","year":"2024","journal-title":"J. Funct. Foods"},{"key":"B50","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3389\/fonc.2016.00274","article-title":"Limb hypothermia for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: a pilot study","volume":"6","author":"Sundar","year":"2017","journal-title":"Front. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.freeradbiomed.2015.06.006","article-title":"Molecular basis of the KEAP1-Nrf2 system","volume":"88","author":"Suzuki","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e151312","DOI":"10.5812\/ijpr-151312","article-title":"Dual COX-2\/TNF-\u03b1 inhibitors as promising anti-inflammatory and cancer chemopreventive agents: a review","volume":"23","author":"Tajdari","year":"2024","journal-title":"Iran. J. Pharm. Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.drudis.2014.07.007","article-title":"Sulforaphane and prostate cancer interception","volume":"19","author":"Traka","year":"2018","journal-title":"Drug Discov. Today"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1166","DOI":"10.7759\/cureus.1144","article-title":"Cardiovascular risk of nonsteroidal anti-inflammatory drugs: an under-recognized public health issue","volume":"9","author":"Varga","year":"2017","journal-title":"Cureus"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.37275\/bsm.v6i9.557","article-title":"Resveratrol as a chemopreventive agent in lung cancer therapy","volume":"6","author":"Verna","year":"2022","journal-title":"Biosci. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/carcin\/bgm275","article-title":"NO-donating aspirin inhibits the activation of NF-\u03baB in human cancer cell lines and Min mice","volume":"29","author":"Williams","year":"2008","journal-title":"Carcinogenesis"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5430\/jst.v6n2p43","article-title":"The impact of cold therapy on the incidence and severity of paclitaxel induced peripheral neuropathy: a pilot study","volume":"6","author":"Younus","year":"2016","journal-title":"J. Solid Tumors"},{"key":"B58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.redox.2017.10.011","article-title":"Reactive oxygen species scavengers ameliorate mechanical allodynia in a rat model of cancer-induced bone pain","volume":"14","author":"Zhou","year":"2017","journal-title":"Redox Biol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1907919\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:41:16Z","timestamp":1788417676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1907919\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":58,"alternative-id":["10.3389\/fphar.2026.1907919"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1907919","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1907919"}}